136 patents
Page 3 of 7
Utility
Modulators of EZH2 expression
21 Jun 22
The present embodiments provide methods, compounds, and compositions useful for inhibiting EZH2 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with EZH2.
Minji Jo, Youngsoo Kim, Robert MacLeod, Susan M. Freier
Filed: 11 Apr 19
Utility
Compositions for modulating C9ORF72 expression
24 May 22
Disclosed herein are compositions and methods for reducing expression of C9ORF72 mRNA and protein in an animal with C9ORF72 specific inhibitors.
Susan M. Freier, Frank Rigo
Filed: 15 Jan 19
Utility
Compounds and methods for reducing LRRK2 expression
17 May 22
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of LRRK2 RNA in a cell or animal, and in certain instances reducing the amount of LRRK2 protein in a cell or animal Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least 5 one symptom or hallmark of a neurodegenerative disease.
Susan M. Freier
Filed: 27 Jun 19
Utility
Modified compounds and uses thereof
17 May 22
The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications.
Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
Filed: 12 Feb 19
Utility
Modulating apolipoprotein (a) expression
3 May 22
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a).
Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu
Filed: 30 Dec 19
Utility
Modulators of diacyglycerol acyltransferase 2 (DGAT2)
26 Apr 22
The present embodiments provide methods, compounds, and compositions useful for inhibiting DGAT2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DGAT2.
Sanjay Bhanot, Susan M. Freier, Eric E. Swayze
Filed: 28 Jun 19
Utility
Compositions and methods for modulating growth hormone receptor expression
26 Apr 22
The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Sanjay Bhanot, Susan M. Freier, Huynh-Hoa Bui
Filed: 4 Aug 20
Utility
Compositions and methods for modulating Ataxin 3 expression
5 Apr 22
Disclosed are methods for modulating splicing of Ataxin 3 mRNA in an animal with modified oligonucleotides.
Frank Rigo, Thazha P. Prakash, Wilhelmina Maria Clasina Van Roon-Mom, Lodewijk Julius Anton Toonen
Filed: 26 Nov 19
Utility
Modulators of MALAT1 expression
22 Mar 22
The present embodiments provide methods, compounds, and compositions useful for inhibiting MALAT1 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with MALAT1.
Susan M. Freier, Youngsoo Kim, Robert MacLeod
Filed: 27 Feb 20
Utility
5′ modified nucleosides and oligomeric compounds prepared therefrom
8 Mar 22
The present invention provides 5′ modified nucleosides and oligomeric compounds prepared therefrom.
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
Filed: 30 Apr 20
Utility
Compounds and methods for modulating C90RF72
1 Mar 22
Disclosed herein are compounds and methods for modulating C9orf72 transcript.
Thazha P. Prakash, Frank Rigo, David Corey
Filed: 2 Nov 16
Utility
Compounds and methods for modulating UBE3A-ATS
1 Mar 22
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A) in a cell or subject, and in certain instances increasing the expression of paternal UBE3A and the amount of UBE3A protein in a cell or subject.
Paymaan Jafar-nejad
Filed: 21 Apr 21
Utility
Modulators of IRF4 expression
8 Feb 22
The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF4 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with IRF4.
Tianyuan Zhou, Youngsoo Kim, Robert MacLeod, Huynh-Hoa Bui, Susan M. Freier
Filed: 1 Mar 19
Utility
Antisense compounds and uses thereof
1 Feb 22
The present invention provides compounds comprising oligonucleotides complementary to a pyruvate kinase M transcript.
Frank Rigo, C. Frank Bennett, Adrian R. Krainer, Zhenxun Wang
Filed: 2 Oct 18
Utility
Modulation of GYS1 expression
1 Feb 22
Provided herein are methods, compounds, and compositions for reducing expression of GYS1 in an individual.
Tamar R. Grossman, Susan M. Freier, Berge Minassian, Saija Ahonen
Filed: 19 Jun 17
Utility
Selective antisense compounds and uses thereof
1 Feb 22
The present invention provides oligomeric compounds.
Michael Oestergaard, Punit P. Seth, Eric E. Swayze
Filed: 18 Feb 20
Utility
Compounds and methods for reducing SNCA expression
25 Jan 22
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SNCA mRNA in a cell or animal, and in certain instances reducing the amount of alpha-synuclein protein in a cell or animal.
Holly Kordasiewicz, Tracy A. Cole
Filed: 9 Nov 18
Utility
Modulation of angiopoietin-like 3 expression
18 Jan 22
Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal.
Rosanne M. Crooke, Mark J. Graham, Richard Lee, Kenneth W. Dobie
Filed: 20 Dec 19
Utility
Modulators of YAP1 expression
4 Jan 22
The present embodiments provide methods, compounds, and compositions useful for inhibiting YAP1 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with YAP1.
Youngsoo Kim, Xiaolin Luo, Robert MacLeod, Susan M. Freier, Huynh-Hoa Bui
Filed: 31 Jan 20
Utility
Modulators of IRF5 expression
28 Dec 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF5 expression, which may be useful for treating, preventing, or ameliorating a disease associated with IRF5.
Susan M. Freier
Filed: 15 Nov 19